• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Shineco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    7/30/25 7:35:46 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SISI alert in real time by email
    false 0001300734 0001300734 2025-07-25 2025-07-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES AND EXCHANGE ACT OF 1934

     

    Date of report (date of earliest event reported): July 25, 2025

     

    SHINECO, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-37776   52-2175898

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    Room 1707, Block D, Modern City SOHO,

    No. 88, Jianguo Road, Chaoyang District,

    Beijing, People’s Republic of China, 100022

    (Address of principal executive offices)

     

    Registrant’s telephone number, including area code: (+86) 10-87227366

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each Class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   SISI   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    As previously disclosed in a Form 8-K filed on June 23, 2025, on June 16, 2025, Shineco Inc. (the “Company”) received a staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) (“Bid Price Rule”) for continued listing on Nasdaq. Furthermore, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Letter notified the Company that it was not eligible for any compliance period, since the Company had effected a reverse stock split over the prior one-year period. The Letter informed the Company that the Company’s securities would be suspended from trading on The Nasdaq Capital Market at the opening of business on June 25, 2025, unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”).

     

    Accordingly, on June 23, 2025, the Company timely requested a hearing before the Panel. On July 24, 2025, the Panel conducted a hearing and the Company attended the hearing (the “Hearing”) regarding the Company’s non-compliance with the Bid Price Rule.

     

    On July 25, 2025, the Company received a letter from the Panel stating that the Panel had determined to deny the Company’s request for continued listing on The Nasdaq Capital Market, and the hearings department informed that trading in the Company’s common stock would be suspended at the open of trading on July 29, 2025 (the “Panel Decision”).

     

    On July 28, 2025, the Company received notice that the Nasdaq Listing and Hearing Review Council (the “Listing Council”), pursuant to its authority under Nasdaq Listing Rule 5820(b), decided to call this matter for review and to grant a stay of the Panel Decision pending the outcome of that review, thereby staying the suspension of trading and delisting of the Company’s common stock pending further review by the Listing Council (the “Listing Council Letter”). Specifically, the Listing Council Letter confirmed that the Listing Council stayed the effectiveness of the July 25, 2025, Panel Decision pending the outcome of the Listing Council’s review process.

     

    The Listing Council permits the Company to submit a memorandum in support of its position, which addresses the basis for the call for review and provides any additional information that the Company wishes the Listing Council to consider as part of its review. The Company’s memorandum must be provided by no later than close of business on August 11, 2025. The Company also is permitted to respond to any submission by the Nasdaq staff by close of business on September 2, 2025. The Company intends to provide additional information to the Listing Council by such dates.

     

    While the Company’s common stock will remain listed on The Nasdaq Stock Market pending the conclusion of the Listing Council’s review, there can be no assurance that the Listing Council ultimately will determine that the Company’s common stock should remain listed on The Nasdaq Stock Market following the completion of its review. Further, there can be no assurance that the Company will be able to satisfy any conditions to continued listing set forth by the Listing Council, should the Listing Council impose such conditions. In the event that the Company is unable to satisfy any such conditions, or if the Listing Council determines that the Company’s securities should not remain listed on The Nasdaq Stock Market, following its review, then trading in the Company’s securities will be suspended on The Nasdaq Stock Market, and the trading suspension will be converted to a delisting at some point thereafter following completion of all Nasdaq administrative processes.

     

    The Company’s operations were not affected by the receipt of the Letter or the Listing Council Letter and are not affected by the Listing Council’s call for review or the Panel Decision. The effect of the Listing Council’s stay of the suspension of trading and delisting is that the Company’s common stock remains listed and trading on The Nasdaq Stock Market without interruption.

     

     

     

     

    Item 8.01. Other Events.

     

    On July 28, 2025, the Company and two of its shareholders (“Plaintiffs”) filed a lawsuit against Nasdaq in the United States District Court for the Southern District of New York (Civil Action No. 1:25-cv-6159) seeking an initial expedited Temporary Restraining Order (“TRO”) to enjoin Nasdaq from suspending trading and delisting the Company’s common stock (“Lawsuit”). Plaintiffs allege Breach of Contract (Warranty), Breach of Contract (Covenant of Good Faith and Fair Dealing), Breach of Contract (Warranty) – Third Party Beneficiaries, and Breach of Contract (Covenant of Good Faith and Fair Dealing) – Third Party Beneficiaries, and seek a Declaratory Judgment. The Lawsuit alleges prospective irreparable harm that would have resulted directly from any suspension and/or delisting of trading of Shineco common stock.

     

    Subsequent to filing of the Lawsuit, the Company received from Nasdaq the Listing Council Letter, which rendered administratively moot the need for the TRO that Plaintiffs sought. On July 29, 2025, as disclosed in a court filing, upon “confirmation [] of the non-interruption and continuation of active trading of Shineco common stock on the Nasdaq [and determining] the TRO Motion became moot,” Plaintiffs withdrew their Motion for the TRO. Plaintiffs did not withdraw the Lawsuit, and the Lawsuit remains pending.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Shineco Inc.
         
    Date: July 30, 2025 By: /s/ Jennifer Zhan
        Jennifer Zhan, Chief Executive Officer

     

     

    Get the next $SISI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SISI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SISI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines

    BEIJING, Sept. 12, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ:SISI) ("Shineco" or the "Company"), a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, today announced two major strategic advances. Its subsidiary, Xi'an Dong'ao Health Management Co., Ltd. ("Dong'ao Health"), has signed a technology services contract valued at US$8.7 million with Xinke Future Biotechnology (Bazhou) Co., Ltd. for the research and development of "microalgae-derived extracellular vesicles" technology. Separately, a delegation from Singapore's leading biotechnology company, BICC, completed a productive site visit to Dong'ao Health on September 10. The parties reached a broad

    9/12/25 9:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries

    BEIJING, Sept. 10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ:SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale production of high-purity, highly active free-form soybean phospholipids. This breakthrough was made possible through its proprietary APCC-UF pure physical extraction technology, overcoming a persistent global technical challenge in the field. Testing by multiple authoritative institutions confirms that the product's key metrics meet internationally leading standards, providing robust technical suppor

    9/10/25 9:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth

    BEIJING, Aug. 27, 2025 /PRNewswire/ -- Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, has entered into a strategic cooperation agreement with Singapore-based BICC Pte Ltd to jointly promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. This collaboration marks a new phase of "cross-enterprise redeemability" for cell assets on the blockchain, advancing the RWA ecosystem from "technical on-chain integration" to "real-world application. This partnership builds on Shineco's prior initiatives: establishing a Cell Digital Division,signing an agree

    8/27/25 6:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Huang Shanchun claimed ownership of 5,041,667 shares (SEC Form 3)

    3 - SHINECO, INC. (0001300734) (Issuer)

    4/24/25 4:05:15 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Yan Chi Keung

    3 - SHINECO, INC. (0001300734) (Issuer)

    12/7/23 4:10:17 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Wang Xiaohui

    3 - SHINECO, INC. (0001300734) (Issuer)

    12/7/23 4:10:16 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    SEC Filings

    View All

    Shineco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - SHINECO, INC. (0001300734) (Filer)

    7/30/25 7:35:46 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEF 14C filed by Shineco Inc.

    DEF 14C - SHINECO, INC. (0001300734) (Filer)

    7/15/25 9:00:11 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - SHINECO, INC. (0001300734) (Filer)

    7/9/25 4:05:57 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    Leadership Updates

    Live Leadership Updates

    View All

    Shineco Establishes Biological Cell Digital Division to Integrate Biological Cell Assets and Blockchain Technology

    BEIJING, Aug. 13, 2025 /PRNewswire/ -- Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, today announced the establishment of a Biological Cell Digital Business Division (the "Division"), and the appointment of Mr. Lin Hongguang as General Manager, to advance the integration of its biological cell assets and blockchain technology. Through a new architecture of blockchain-based cell assets, Shineco aims to build a vertical ecosystem within the biological cell sector, accelerate the global distribution of biological cell products and boost global sales. The Division is expected to use blockchain technol

    8/13/25 6:30:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    Future FinTech Announces the Appointment of Hu Li as the New CEO

    NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Future Fintech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"), a comprehensive financial and digital technology service provider, today announced that its Board of Directors (the "Board") approved the appointment of Mr. Hu Li as Chief Executive Officer ("CEO"), President and a member of the Board of the Company, effective August 5, 2024. Mr. Li will be fully responsible for the operation and management of the Company, helping it to expand internationally, manage its investment and financi

    8/9/24 9:00:00 AM ET
    $FTFT
    $SISI
    Real Estate
    Medicinal Chemicals and Botanical Products
    Health Care

    Shineco Announces the Appointment of Two New Executive Officers

    BEIJING, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of technologically advanced healthcare products and services, announced today that its Board of Directors has appointed Ms. Xiaohui Wang and Mr. Chi Keung Yan as executive officers of the Company in key leadership roles. Effective November 13, 2023, Shineco's Board of Directors appointed Ms. Xiaohui Wang as Executive President of the Company. From March 2000 to November 2013, Ms. Wang was the founder and Chairperson of Chongqing Wintus (New Star) Enterprises Group, where she was responsible for its corporate planning, supervision of the group's business in the Chongqing region,

    11/17/23 9:00:00 AM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    $SISI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Shineco Inc.

    SC 13G/A - SHINECO, INC. (0001300734) (Subject)

    10/25/24 2:45:17 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Shineco Inc.

    SC 13D - SHINECO, INC. (0001300734) (Subject)

    7/12/24 5:28:03 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Shineco Inc.

    SC 13G - SHINECO, INC. (0001300734) (Subject)

    8/29/23 1:26:38 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care